SAP

sap.com

SAP is a global software application vendor. SAP is the market leader in enterprise application software, helping companies of all sizes and in all industries run at their best: 77% of the world’s transaction revenue touches an SAP system. Our machine learning, Internet of Things (IoT), and advanced analytics technologies help turn customers’ businesses into intelligent enterprises. Our end-to-end suite of applications and services enables our customers to operate profitably, adapt continuously, and make a difference. With a global network of customers, partners, employees, and thought leaders, SAP helps the world run better and improves people’s lives.

C-Suite On Deck

Q&A with Tom Raftery, Global VP at SAP

MEDIA 7 | September 19, 2019

Tom Raftery, Global VP at SAP is an Innovation Evangelist, Futurist, and international Keynote speaker. Prior to joining SAP, Tom worked for a number of companies at Group IT Manager/CTO level, and as an Industry Analyst. Tom is a global thought leader and ranks among the top 10 Internet of Things influencers in the world. MEDIA 7: If I were to say to a bunch of people who know you, ‘Give me three adjectives that best describe you’, what would I hear? TOM RAFTERY: I would like to think that I am a good communicator, maybe smart and hopefully generous. You will have to ask people other than myself though. They would be a better judge. M7: What is the role of a technology influencer in driving environmental sustainability? TR: The role of someone like me would be to raise awareness of the issues that are happening and potential solutions to them, particularly technological solutions. A lot of people are busy in their day-to-day lives and they might not be aware of some of the more pressing environmental issues that are happening in the world and that might impact them. So, raising awareness with people, of the importance of these issues, and the potential technological solutions to them is the role I think that influencers should be playing.

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

DESPITE GOVERNMENT SHUTDOWN, EXELIXIS SNAGS FDA APPROVAL FOR HCC DRUG CABOMETYX

Biosapce.com | January 15, 2019

Shares of Alameda, Calif.-based Exelixis are climbing after the U.S. Food and Drug Administration (FDA) approved its hepatocellular carcinoma (HCC) treatment Cabometyx (cabozantinib). It was previously approved for the treatment of patients with advanced renal cell carcinoma. The approval came despite a partial government shutdown that will likely delay a number of potential approvals unless funding is restored to the regulatory agency. Exelixis’ Cabometyx was approved for HCC patients who...

BMS’ OPDIVO DISAPPOINTS IN LATE-STAGE TRIAL

pharmatimes | June 26, 2019

Bristol-Myers Squibb has announced topline results from its CheckMate -459 trial evaluating Opdivo (nivolumab) in patients with unresectable hepatocellular carcinoma (HCC). The results show that the cancer drug failed to show superiority to Nexavar (sorafenib), and did not achieve statistical significance for its primary endpoint of overall survival. The news isn’t all negative, however, as a clear trend was demonstrated towards improvement in overall survival for patients treated with Opd...

AZ COPD DRUG FAILS TO MATCH GSK RIVAL AFTER DISAPPOINTING LAUNCH

Pharmaphorum Media Limited | August 23, 2018

AstraZeneca has said it is analyzing “inconsistent” results after a late-stage trial of its Bevespi Aerosphere inhaler in chronic obstructive pulmonary disease (COPD) failed to match the performance of GlaxoSmithKline’s rival. Already approved in the US and on the market since early last year, Bevespi (glycopyrronium/formoterol fumarate) is under review in Europe. While trials used as a basis for approval in the US and Asia have tested Bevespi against placebo, the latest trial,...

MORE PATIENTS CAN NOW BE TREATED WITH NEW SAPIEN 3 ULTRA TRANSCATHETER AORTIC VALVE

Medgadget | January 02, 2019

Edwards Lifesciences received FDA approval to introduce its SAPIEN 3 Ultra transcatheter aortic heart valve in the U.S. Specifically, the device is indicated for cases of severe, symptomatic aortic stenosis identified to be at the intermediate or greater risk of open-heart surgery. The SAPIEN 3 Ultra has some modifications that make it appropriate to a wider range of patients that would otherwise not be able to get a transcatheter aortic valve. And a brand new delivery system and sheath make the...